# Phase 5 QA Sign-Off Form

**Release:** QMS Agent v1.0 — Phase 5 System Validation & Production Rollout  
**Form Date:** \_**\_/\_\_**/2025  
**Classification:** REGULATORY EVIDENCE — CONFIDENTIAL

---

## Multi-Authority Approval Gate

This form certifies that QMS Agent v1.0 has been validated in accordance with ISO 13485:2016 and FDA 21 CFR Part 11, and is approved for production release.

---

## SECTION 1: Test Execution Summary

**Validation Period:** 12/09/2025 — 12/24/2025  
**Test Environment:** ☐ Dev ☐ Staging ☐ Pre-Prod ☐ Production (validation)  
**Portal URL:** https://********\_\_\_********

### Test Metrics

| Metric               | Value  | Status       |
| -------------------- | ------ | ------------ |
| **Total Test Cases** | 25     | ☐ COMPLETE   |
| **Tests Executed**   | \_\_\_ | ☐ 100%       |
| **Tests Passed**     | \_\_\_ | ☐ ≥ 90%      |
| **Tests Failed**     | \_\_\_ | ☐ ≤ 2        |
| **Tests Blocked**    | \_\_\_ | ☐ 0          |
| **Pass Rate**        | \_\_%  | ☐ ACCEPTABLE |

### Results by Category

| Category        | Tests  | Passed     | Failed     | Blocked | Rate        | Status     |
| --------------- | ------ | ---------- | ---------- | ------- | ----------- | ---------- |
| A (UI)          | 4      | \_\_\_     | \_\_\_     | 0       | \_\_%       | ☐ PASS     |
| B (LLM)         | 4      | \_\_\_     | \_\_\_     | 0       | \_\_%       | ☐ PASS     |
| C (Auth)        | 8      | \_\_\_     | \_\_\_     | 0       | \_\_%       | ☐ PASS     |
| D (Audit)       | 4      | \_\_\_     | \_\_\_     | 0       | \_\_%       | ☐ PASS     |
| E (Performance) | 2      | \_\_\_     | \_\_\_     | 0       | \_\_%       | ☐ PASS     |
| F (Compliance)  | 5      | \_\_\_     | \_\_\_     | 0       | \_\_%       | ☐ PASS     |
| **TOTAL**       | **25** | **\_\_\_** | **\_\_\_** | **0**   | **\_\_\_%** | **☐ PASS** |

---

## SECTION 2: Regulatory Compliance Verification

### 2.1 ISO 13485:2016 Requirements

✓ = Requirement met with evidence  
✗ = Requirement not met  
⚠ = Conditional (met with conditions)

| Clause      | Requirement                                                     | Test Case      | Evidence                                                        | Verified |
| ----------- | --------------------------------------------------------------- | -------------- | --------------------------------------------------------------- | -------- |
| **7.3.6**   | Automatic system must record audit trail for electronic records | ISO_7.3.6      | Phase5-Evidence/Category_F_Compliance/ISO_13485_Clause_7.3.6/   | ☐ ✓      |
| **7.5.4.2** | User identification & authentication required for system access | 4D-001, 4D-004 | Phase5-Evidence/Category_F_Compliance/ISO_13485_Clause_7.5.4.2/ | ☐ ✓      |
| **7.5.4.3** | Automated system decisions reviewed by qualified person         | ISO_7.5.4.3    | Phase5-Evidence/Category_F_Compliance/ISO_13485_Clause_7.5.4.3/ | ☐ ✓      |

**Overall ISO 13485 Compliance:** ☐ COMPLIANT ☐ NON-COMPLIANT ☐ CONDITIONAL

---

### 2.2 FDA 21 CFR Part 11 Requirements

| Section       | Requirement                                                 | Test Case        | Evidence                                                          | Verified |
| ------------- | ----------------------------------------------------------- | ---------------- | ----------------------------------------------------------------- | -------- |
| **11.10(e)**  | Complete, accurate audit trail; append-only; immutable      | 4CD-002, 4CD-004 | Phase5-Evidence/Category_D_Audit/4CD-002_Audit_Trail_E2E/         | ☐ ✓      |
| **11.100**    | User authentication; unique user ID; secure password/method | 4D-001, 4D-005   | Phase5-Evidence/Category_F_Compliance/FDA_21CFR11_Section_11.100/ | ☐ ✓      |
| **11.100(a)** | System prevents unauthorized access                         | 4D-002, 4D-003   | Phase5-Evidence/Category_C_Auth/4D-002_RBAC_Deny_Engineer/        | ☐ ✓      |
| **11.100(b)** | Session timeout (8 hrs max)                                 | 4D-005           | Phase5-Evidence/Category_C_Auth/4D-005_Session_Timeout/           | ☐ ✓      |

**Overall FDA 21 CFR 11 Compliance:** ☐ COMPLIANT ☐ NON-COMPLIANT ☐ CONDITIONAL

---

## SECTION 3: Critical Defect Resolution

### 3.1 Outstanding Defects

| NCR #  | Test Case | Severity | Status   | Resolution | Verified |
| ------ | --------- | -------- | -------- | ---------- | -------- |
| (None) | —         | —        | RESOLVED | —          | ☐ YES    |
|        |           |          |          |            |          |
|        |           |          |          |            |          |

**All Critical Defects Resolved:** ☐ YES ☐ NO

### 3.2 Known Issues & Risk Mitigation

| Issue              | Impact | Mitigation | Owner | Target Date |
| ------------------ | ------ | ---------- | ----- | ----------- |
| (None outstanding) | —      | —          | —     | —           |

---

## SECTION 4: Performance & Load Testing Results

| Metric                             | Target   | Actual       | Status | Evidence        |
| ---------------------------------- | -------- | ------------ | ------ | --------------- |
| AI Chat Response Time (p50)        | < 2 sec  | \_\_\_ sec   | ☐ MET  | 4CD-003         |
| AI Chat Response Time (p95)        | < 3 sec  | \_\_\_ sec   | ☐ MET  | 4CD-003         |
| Concurrent Users Supported         | ≥ 100    | \_\_\_ users | ☐ MET  | 4CD-003         |
| Conversation State (100+ messages) | Stable   | ✓            | ☐ MET  | 4C-007-Extended |
| Browser Memory Usage               | < 100 MB | \_\_\_ MB    | ☐ MET  | 4C-007-Extended |

**Performance Baselines Achieved:** ☐ YES ☐ NO

---

## SECTION 5: Audit Trail Integrity & Security

### 5.1 Audit Trail Verification

| Criterion           | Expected                                                     | Actual                         | Verified |
| ------------------- | ------------------------------------------------------------ | ------------------------------ | -------- |
| **Immutability**    | Audit records cannot be modified or deleted                  | [Verified via 4CD-002]         | ☐ YES    |
| **Completeness**    | All system actions logged with required fields               | [Verified via 4D-007]          | ☐ YES    |
| **Traceability**    | Linked chain of events (userId, sessionId, action, resource) | [Verified via 4CD-005]         | ☐ YES    |
| **Append-Only**     | New events appended; no overwriting                          | [Verified via BigQuery schema] | ☐ YES    |
| **Time-Ordered**    | Events in chronological sequence                             | [Verified via ISO_7.3.6]       | ☐ YES    |
| **No PII Exposure** | Audit logs contain no plaintext secrets/passwords            | [Verified via 4CD-004]         | ☐ YES    |

**Audit Trail Integrity:** ☐ VERIFIED ☐ NOT VERIFIED

### 5.2 Security Audit Results

| Check                          | Result | Evidence                                              |
| ------------------------------ | ------ | ----------------------------------------------------- |
| OAuth 2.0 flow compliance      | ✓ PASS | 4D-001                                                |
| JWT token validation           | ✓ PASS | Phase5-Evidence/Category_C_Auth/4D-001_OAuth_Sign_In/ |
| RBAC permission enforcement    | ✓ PASS | 4D-004                                                |
| Session timeout enforcement    | ✓ PASS | 4D-005                                                |
| No SQL injection vulnerability | ✓ PASS | Security scan (reference)                             |
| No PII in logs                 | ✓ PASS | 4CD-004                                               |

**Security Audit Status:** ☐ PASS ☐ FAIL ☐ PASS WITH EXCEPTIONS

---

## SECTION 6: Documentation & Evidence

### 6.1 Deliverables Checklist

| Deliverable                     | Status     | Location                                                  |
| ------------------------------- | ---------- | --------------------------------------------------------- |
| Test Execution Log              | ☐ COMPLETE | PHASE5-EXECUTION-LOG-TEMPLATE.md                          |
| Evidence Directory Structure    | ☐ COMPLETE | Phase5-Evidence/ (PHASE5-EVIDENCE-DIRECTORY-STRUCTURE.md) |
| Test Result Documents (25×)     | ☐ COMPLETE | Phase5-Evidence/Category\_\*/test_result.md               |
| Screenshots & DevTools Captures | ☐ COMPLETE | Phase5-Evidence/Category\__/_.png, \*.json                |
| BigQuery Audit Trail Export     | ☐ COMPLETE | Phase5-Evidence/Category_D_Audit/                         |
| Load Test Results (JMeter)      | ☐ COMPLETE | Phase5-Evidence/Category_E_Performance/                   |
| ISO 13485 Compliance Mapping    | ☐ COMPLETE | Phase5-Evidence/Category_F_Compliance/                    |
| FDA 21 CFR 11 Mapping           | ☐ COMPLETE | Phase5-Evidence/Category_F_Compliance/                    |
| Final Validation Report         | ☐ COMPLETE | PHASE5-FINAL-VALIDATION-REPORT.md                         |

**All Evidence Collected:** ☐ YES ☐ NO

### 6.2 Evidence Retention

- **Archive Location:** [GCS Archive / Offline Tape / Other: _______________]
- **Backup Strategy:** [Daily / Weekly / Other: _______________]
- **Retention Period:** 7+ years (per FDA 21 CFR 11)
- **Archive Checksum (SHA-256):** ****************\_\_\_****************

---

## SECTION 7: Authority Sign-Offs

All five regulatory authorities must verify the above sections and sign below. Signatures certify that the signatory has reviewed the evidence in Phase5-Evidence/ and agrees with the stated conclusions.

---

### **SIGNATURE 1: Engineering Lead**

**Authority:** Engineering team responsible for system design & implementation

**Review Checklist:**

- ☐ I have reviewed PHASE5-EXECUTION-LOG-TEMPLATE.md (Section 2.2 results)
- ☐ I have reviewed Phase5-Evidence/Category_B_LLM/ (LLM functionality tests)
- ☐ I have reviewed Phase5-Evidence/Category_C_Auth/ (Auth integration tests)
- ☐ I confirm that Phase 4C & 4D code has been tested and defects resolved
- ☐ I confirm the system is ready for production deployment

**Statement:**
The Engineering team attests that QMS Agent v1.0 Phase 4C (LLM Assistant) and Phase 4D (Authentication/RBAC) have been implemented, tested, and are ready for production release. All critical defects have been resolved and verified.

**Name:** ************\_\_\_************  
**Title:** Engineering Lead  
**Email:** ************\_\_\_************  
**Organization:** ************\_\_\_************  
**Signature:** **********\_\_\_\_********** **Date:** \_**\_/\_\_**/2025  
**Time Signed:** \_**\_:\_\_** (24-hr)

---

### **SIGNATURE 2: QA Lead**

**Authority:** QA team responsible for test execution & validation

**Review Checklist:**

- ☐ I have reviewed PHASE5-EXECUTION-LOG-TEMPLATE.md (daily logs & summary)
- ☐ I have reviewed all Phase5-Evidence/ folders (25 test cases)
- ☐ I have verified all test results and documented evidence
- ☐ I confirm that pass rate ≥ 90% and all blockers resolved
- ☐ I confirm the validation period (12/09–12/24/2025) was completed

**Statement:**
The QA team attests that all 25 validation test cases have been executed in accordance with the Phase 5 Validation Protocol. Evidence has been captured, organized, and documented. The system achieves **_% pass rate ([_**] tests passed, [___] tests failed). All test failures have been investigated and resolved.

**Name:** ************\_\_\_************  
**Title:** QA Lead  
**Email:** ************\_\_\_************  
**Organization:** ************\_\_\_************  
**Signature:** **********\_\_\_\_********** **Date:** \_**\_/\_\_**/2025  
**Time Signed:** \_**\_:\_\_** (24-hr)

---

### **SIGNATURE 3: Quality Manager**

**Authority:** Quality Management system oversight; regulatory compliance

**Review Checklist:**

- ☐ I have reviewed PHASE5-FINAL-VALIDATION-REPORT.md
- ☐ I have verified ISO 13485:2016 Clause 7.3.6, 7.5.4.2, 7.5.4.3 compliance
- ☐ I have verified FDA 21 CFR 11 Section 11.10, 11.100 compliance
- ☐ I have reviewed Phase5-Evidence/Category_F_Compliance/ (regulatory mapping)
- ☐ I confirm the product is safe for production release
- ☐ No residual critical risks remain

**Compliance Statement:**
The Quality Manager attests that QMS Agent v1.0 has been validated in full compliance with ISO 13485:2016 and FDA 21 CFR Part 11 requirements. The product is safe for production release to end users. All required regulatory evidence has been generated, documented, and archived for 7-year retention.

**Name:** ************\_\_\_************  
**Title:** Quality Manager  
**Email:** ************\_\_\_************  
**Organization:** ************\_\_\_************  
**Signature:** **********\_\_\_\_********** **Date:** \_**\_/\_\_**/2025  
**Time Signed:** \_**\_:\_\_** (24-hr)

---

### **SIGNATURE 4: Compliance Officer**

**Authority:** Regulatory compliance; FDA inspection readiness

**Review Checklist:**

- ☐ I have reviewed Phase5-Evidence/Category_F_Compliance/ (ISO & FDA requirements)
- ☐ I have reviewed Phase5-Evidence/Category_D_Audit/ (audit trail & traceability)
- ☐ I have verified 7-year retention policy implementation
- ☐ I have verified audit trail immutability & append-only enforcement
- ☐ I confirm all FDA 21 CFR 11 & ISO 13485 requirements are met
- ☐ I confirm the system is audit-ready for FDA inspection

**Regulatory Statement:**
The Compliance Officer attests that all validation activities conform to 21 CFR Part 11 and ISO 13485:2016 standards. The system is ready for FDA inspection. Adequate evidence has been generated and retained for regulatory review. No regulatory gaps or non-conformances remain outstanding.

**Name:** ************\_\_\_************  
**Title:** Compliance Officer  
**Email:** ************\_\_\_************  
**Organization:** ************\_\_\_************  
**Signature:** **********\_\_\_\_********** **Date:** \_**\_/\_\_**/2025  
**Time Signed:** \_**\_:\_\_** (24-hr)

---

### **SIGNATURE 5: Production Manager**

**Authority:** Production environment readiness; deployment authorization

**Review Checklist:**

- ☐ I have verified production infrastructure is ready
- ☐ I have verified backup & disaster recovery procedures
- ☐ I have verified rollback procedures in place
- ☐ I have verified monitoring & alerting configured
- ☐ I have verified user access controls & API keys configured
- ☐ Production deployment can proceed safely

**Deployment Statement:**
The Production Manager attests that the production environment is ready for deployment of QMS Agent v1.0. All infrastructure, backup, monitoring, and security controls have been validated. Rollback procedures are documented and tested. Production release can proceed safely.

**Name:** ************\_\_\_************  
**Title:** Production Manager  
**Email:** ************\_\_\_************  
**Organization:** ************\_\_\_************  
**Signature:** **********\_\_\_\_********** **Date:** \_**\_/\_\_**/2025  
**Time Signed:** \_**\_:\_\_** (24-hr)

---

## SECTION 8: Final Release Decision

### Approval Matrix

| Authority          | Status                | Date Signed        | Notes |
| ------------------ | --------------------- | ------------------ | ----- |
| Engineering Lead   | ☐ APPROVED ☐ REJECTED | \_**\_/\_\_**/2025 |       |
| QA Lead            | ☐ APPROVED ☐ REJECTED | \_**\_/\_\_**/2025 |       |
| Quality Manager    | ☐ APPROVED ☐ REJECTED | \_**\_/\_\_**/2025 |       |
| Compliance Officer | ☐ APPROVED ☐ REJECTED | \_**\_/\_\_**/2025 |       |
| Production Manager | ☐ APPROVED ☐ REJECTED | \_**\_/\_\_**/2025 |       |

### Final Release Decision

**All 5 Authorities Approved:** ☐ YES ☐ NO

**Final Decision:** ☐ **APPROVED FOR PRODUCTION** ☐ **APPROVED WITH CONDITIONS** ☐ **REJECTED**

### Conditions (if applicable)

[List any conditions that must be met before production release]

---

### Release Authorization

**Authorized By:** ************\_\_\_************  
**Title:** Quality Manager (Release Authority)  
**Signature:** **********\_\_\_\_********** **Date:** \_**\_/\_\_**/2025  
**Time:** \_**\_:\_\_** (24-hr)

**Release Notes:**

- **Product:** QMS Agent v1.0
- **Phase:** Phase 5 System Validation & Production Rollout
- **Release Date:** \_**\_/\_\_**/2025
- **Deployment Environment:** Production
- **Deployment Cutover Date:** \_**\_/\_\_**/2025 at \_**\_:\_\_** (UTC)

---

## SECTION 9: Document Control & Archive

### Document Metadata

| Property             | Value                                     |
| -------------------- | ----------------------------------------- |
| **Document ID**      | PHASE5-QA-SIGN-OFF-FORM-v1.0              |
| **Title**            | Phase 5 QA Sign-Off Form — QMS Agent v1.0 |
| **Version**          | 1.0                                       |
| **Release Date**     | \_**\_/\_\_**/2025                        |
| **Author**           | QA Team                                   |
| **Classification**   | REGULATORY EVIDENCE — CONFIDENTIAL        |
| **Retention Period** | 7+ years (per FDA 21 CFR 11)              |
| **Archive Location** | [GCS Archive / Offline Tape]              |
| **Archival Date**    | \_**\_/\_\_**/2025                        |

### Archive Checklist

- ☐ All signatures collected
- ☐ Document scanned (if handwritten signatures)
- ☐ SHA-256 checksum calculated
- ☐ Uploaded to archive storage (GCS Archive / Tape)
- ☐ Backup copy created (off-site)
- ☐ Access control verified (Quality/Compliance only)
- ☐ Retention period logged in document management system

**Archive Verified By:** ************\_\_\_************  
**Date:** \_**\_/\_\_**/2025

---

**This document certifies that QMS Agent v1.0 Phase 5 validation has been completed in accordance with ISO 13485:2016 and FDA 21 CFR Part 11, and that the product is approved for production release.**

**Unauthorized reproduction or disclosure is prohibited. For 7-year retention per FDA 21 CFR 11 and ISO 13485.**
